
1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

MATERIAL NAME: Dopamine Hydrochloride Injection, USP; Dopamine Hydrochloride in 5% Dextrose Injection, USP
List Number: 4141, 4142, 4155, 4265, 4266, 5809, 5819, 5820, 7772, 7808, 7809, 7810, 9104, 9105

MANUFACTURER: Hospital Products Division
Abbott Laboratories
Abbott Park, Illinois 60064

EMERGENCY TELEPHONE NUMBER: 1-847-937-7970
CHEMTREC TELEPHONE NUMBER: 1-800-424-9300

2. COMPOSITION/INFORMATION ON INGREDIENTS

INGREDIENT NAME: Dopamine Hydrochloride *
CAS/RTECS NUMBERS: 62-31-7 / UX1092000
OSHA-PEL 8HR TWA: N/L
STEL: N/L
CEILING: N/L
ACGIH-TLV 8HR TWA: N/L
STEL: N/L
CEILING: N/L
OTHER 8HR TWA: N/A
LIMITS STEL: 100 mcg/m3 (Abbott Laboratories)
CEILING: N/A

* Hazardous per OSHA criteria

3. HAZARDS INFORMATION

EMERGENCY OVERVIEW: In clinical use, this material is used to treat shock and other emergencies. The active ingredient stimulates the sympathetic nervous system increasing cardiac output. It is a potent drug. Target organs include the cardiovascular system and, in the rat, the fetus.

Dopamine Hydrochloride Injection, USP

ISSUED 12/27/96

3. HAZARDS INFORMATION, continued

ROUTE(S) OF ENTRY: Skin: Unlikely
 Inhalation: Unlikely
 Ingestion: Unlikely

INGESTION RATING: None

SKIN ABSORPTION RATING: N/D

INHALATION RATING: N/D

CORROSIVENESS RATING: N/D

SKIN CONTACT RATING: N/D

SKIN SENSITIZATION RATING: N/D

EYE CONTACT RATING: N/D

TARGET ORGANS: Cardiovascular system, fetus (in rats)

CARCINOGENICITY RATING: NTP: N/L IARC: N/L OSHA: N/L
 ACGIH: N/L
 None

SIGNS AND SYMPTOMS: N/D. In clinical use, dopamine can cause ectopic heart beats, nausea, vomiting, increased heart rate, anginal pain, palpitations, difficulty breathing, headache, hypotension and constriction of blood vessels.

MEDICAL CONDITIONS AGGRAVATED BY EXPOSURE: N/D. Pheochromocytoma, uncorrected tachyarrhythmia or ventricular arrhythmia, concurrent monoamine oxidase inhibitor therapy, hypovolemia and cardiovascular diseases. Hypersensitivity to metabisulfites.

Dopamine Hydrochloride Injection, USP

ISSUED 12/27/96

4. FIRST AID MEASURES

EYES: Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. No known antidote. Provide symptomatic/supportive care, monitoring blood pressure and cardiovascular function, as necessary. Alpha blocking agents may be helpful to stabilize the patient's condition.

SKIN: Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. No known antidote. Provide symptomatic/supportive care, monitoring blood pressure and cardiovascular function, as necessary. Alpha blocking agents may be helpful to stabilize the patient's condition.

INGESTION: Remove from source of exposure. If signs of toxicity occur, seek medical attention. No known antidote. Provide symptomatic/supportive care, monitoring blood pressure and cardiovascular function, as necessary. Alpha blocking agents may be helpful to stabilize the patient's condition.

INHALATION: Remove from source of exposure. If signs of toxicity occur, seek medical attention. No known antidote. Provide symptomatic/supportive care, monitoring blood pressure and cardiovascular function, as necessary. Alpha blocking agents may be helpful to stabilize the patient's condition.

5. FIRE FIGHTING PROCEDURES

FLASH POINT: N/A

FLASH POINT METHOD: N/A

LOWER EXPLOSIVE LIMIT(%): N/D

UPPER EXPLOSIVE LIMIT(%): N/D

AUTOIGNITION TEMPERATURE: N/A

FIRE & EXPLOSION HAZARDS: N/D

EXTINGUISHING MEDIA: Use media appropriate for primary cause of fire.

Dopamine Hydrochloride Injection, USP

ISSUED 12/27/96

5. FIRE FIGHTING PROCEDURES, continued

FIRE FIGHTING INSTRUCTIONS: Fire fighters should wear self-contained breathing apparatus, flame and chemical resistant clothing, boots and gloves.

6. ACCIDENTAL RELEASE MEASURES

SPILL OR RELEASE PROCEDURES: Absorb with suitable material and place into container for disposal in accordance with Section 13.

7. HANDLING AND STORAGE

HANDLING: Avoid excessive heat. Protect from freezing.

STORAGE: Store at controlled room temperature of 25 degrees C.

SPECIAL PRECAUTIONS: Protect from heat and freezing temperatures.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

ENGINEERING CONTROLS: No special provisions are required under normal product use.

RESPIRATORY PROTECTION: Respiratory protection is not needed during normal product use.

SKIN PROTECTION: If skin contact is likely, impervious gloves are recommended.

EYE PROTECTION: Eye protection is not required during typical product use conditions. Eye protection is recommended if contact is likely.

OTHER PROTECTION: N/D

Dopamine Hydrochloride Injection, USP

ISSUED 12/27/96

9. PHYSICAL AND CHEMICAL PROPERTIES

APPEARANCE/PHYSICAL STATE: Clear, colorless to light yellow solution.

ODOR: N/D

BOILING POINT: Water (approx.)

MELTING/FREEZING POINT: Water (approx.)

VAPOR PRESSURE (mm Hg): N/D

VAPOR DENSITY (Air=1): N/D

EVAPORATION RATE: N/D

BULK DENSITY: N/D

SPECIFIC GRAVITY: 1.016 - 1.36

SOLUBILITY: Water

pH: 2.5 - 5.0

VISCOSITY: 1.13 - 1.30 cps at 25 deg. C

10. STABILITY AND REACTIVITY

CHEMICAL STABILITY: N/D

INCOMPATIBILITIES: Alkalies (including sodium bicarbonate), oxidizing agents or iron salts.

HAZARDOUS DECOMPOSITION PRODUCTS: When heated to decomposition it emits very toxic fumes of NOx and HCl.

HAZARDOUS POLYMERIZATION: N/D

11. TOXICOLOGICAL INFORMATION

ORAL TOXICITY: N/D. LD50 = 2859-4361 mg/kg in mice and rats for dopamine hydrochloride.

DERMAL TOXICITY: N/D

INHALATION TOXICITY: N/D

CORROSIVENESS: N/D

DERMAL IRRITATION: N/D

Dopamine Hydrochloride Injection, USP

ISSUED 12/27/96

11. TOXICOLOGICAL INFORMATION, continued

OCULAR IRRITATION: N/D

DERMAL SENSITIZATION: N/D

SPECIAL TARGET ORGAN EFFECTS: N/D. In clinical use, dopamine stimulates the sympathetic nervous system increasing cardiac output. In one study in pregnant rats, dopamine hydrochloride decreased survival of the pups.

CARCINOGENICITY INFORMATION: N/D

12. ECOLOGICAL INFORMATION

ECOLOGICAL INFORMATION: N/D

13. DISPOSAL CONSIDERATIONS

WASTE DISPOSAL METHODS: Dispose of in accordance with local, state and federal regulations.

14. TRANSPORTATION INFORMATION

DOT STATUS: Not Regulated
PROPER SHIPPING NAME: N/A
HAZARD CLASS: N/A
UN NUMBER: N/A
PACKING GROUP: N/A
REPORTABLE QUANTITY: N/A

Dopamine Hydrochloride Injection, USP

ISSUED 12/27/96

14. TRANSPORTATION INFORMATION, continued

IATA/ICAO STATUS: Not Regulated

PROPER SHIPPING NAME: N/A

HAZARD CLASS: N/A

UN NUMBER: N/A

PACKING GROUP: N/A

REPORTABLE QUANTITY: N/A

IMO STATUS: Not Regulated

PROPER SHIPPING NAME: N/A

HAZARD CLASS: N/A

UN NUMBER: N/A

PACKING GROUP: N/A

REPORTABLE QUANTITY: N/A

FLASH POINT: N/A

15. REGULATORY INFORMATION

TSCA STATUS: N/A

CERCLA STATUS: N/L

SARA STATUS: N/L

RCRA STATUS: N/L

PROP 65 (CA): N/D

Dopamine Hydrochloride Injection, USP

ISSUED 12/27/96

16. OTHER INFORMATION

LEGEND: N/A = Not Applicable
N/D = Not Determined
N/L = Not Listed
L = Listed
C = Ceiling
S = Short-term
(R) = Registered Trademark of Abbott Laboratories
(TM) = Registered Trademark of Abbott Laboratories

The information and recommendations contained herein are based upon tests believed to be reliable. However, Abbott Laboratories does not guarantee their accuracy or completeness nor shall any of this information constitute a warranty, whether expressed or implied, as to the safety of the goods, the merchantability of the goods, or the fitness of the goods for a particular purpose. Adjustment to conform with actual conditions of usage may be required. Abbott Laboratories assumes no responsibility for results obtained or for incidental or consequential damages arising from the use of these data. No freedom from infringement of any patent, copyright or trademark is to be inferred.

APPROVED BY: FM